Amgen Inc. (AMGN) Stake Decreased by Beck Mack & Oliver LLC

Beck Mack & Oliver LLC cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 6.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,200 shares of the medical research company’s stock after selling 400 shares during the quarter. Beck Mack & Oliver LLC’s holdings in Amgen were worth $1,068,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Camelot Portfolios LLC acquired a new position in shares of Amgen during the 1st quarter worth $1,429,000. PGGM Investments grew its stake in shares of Amgen by 2.3% during the 2nd quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after purchasing an additional 15,059 shares during the period. Shelton Capital Management grew its stake in shares of Amgen by 82.7% during the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares during the period. Greylin Investment Mangement Inc. grew its stake in shares of Amgen by 466.9% during the 2nd quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after purchasing an additional 11,555 shares during the period. Finally, Cadence Bank NA grew its stake in shares of Amgen by 6.2% during the 1st quarter. Cadence Bank NA now owns 3,376 shares of the medical research company’s stock worth $554,000 after purchasing an additional 197 shares during the period. 78.09% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently commented on the stock. Cann reiterated a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG assumed coverage on shares of Amgen in a research report on Friday, June 23rd. They issued a “hold” rating and a $172.00 price objective on the stock. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, William Blair reiterated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Amgen presently has an average rating of “Buy” and a consensus target price of $186.14.

TRADEMARK VIOLATION NOTICE: This news story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/09/20/amgen-inc-amgn-stake-decreased-by-beck-mack-oliver-llc.html.

Amgen Inc. (AMGN) opened at 186.32 on Wednesday. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The stock’s 50 day moving average is $175.99 and its 200 day moving average is $169.31. The stock has a market capitalization of $135.95 billion, a price-to-earnings ratio of 16.97 and a beta of 1.35.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the company posted $2.84 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts forecast that Amgen Inc. will post $12.57 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.47%. Amgen’s payout ratio is presently 41.93%.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply